Topics:

Melanoma

Immunotherapy Combination Active in Advanced Melanoma

Treatment with nivolumab and ipilimumab in patients with advanced melanoma produced significantly higher rates of response and progression-free survival compared with ipilimumab alone.

Melanoma

(Courtesy David Schwartz, MD)

There is a lot of new information about the link between various malignancies and inflammatory bowel disease. Here: answers to 3 key questions.

Treatment with nivolumab and ipilimumab in patients with advanced melanoma produced significantly higher rates of response and progression-free survival compared with ipilimumab alone.

Treatment with pembrolizumab resulted in an estimated 6-month PFS rate that was almost double that of treatment with ipilimumab in advanced melanoma patients.

Advanced melanoma patients who progressed on ipilimumab were more likely to achieve an objective response when treated with nivolumab than with chemotherapy.

The measurement of levels of C-reactive protein (CRP) in the blood has been found to be an independent prognostic marker for survival in patients with melanoma.

Advanced melanoma patients who received front-line ipilimumab/dacarbazine had double the 5-year survival rate compared with those on dacarbazine alone.

A single-institution study found that patients with melanomas of 4 mm thickness who had a negative sentinel lymph node biopsy had significantly prolonged survival.

Pages

Subscribe to Melanoma on [sitename]
  • When you inspect moles, pay special attention to their sizes, shapes, edges, and color. A handy way to remember these features is to think of the A, B, C, D, and E of skin cancer—asymmetry, border, color, diameter, and evolving.

By clicking Accept, you agree to become a member of the UBM Medica Community.